The Europe Apheresis Market would witness market growth of 7.6% CAGR during the forecast period (2022-2028).
Disease such as Sickle cell is a genetic disease where the red blood cells are abnormally shaped like sickles and cannot effectively transfer oxygen around the body. If they create a sickle cell emergency, their sickled red blood cells can be scrapped and substituted with healthy cells from a blood donor via erythrocytapheresis.
Patients with leukemia may have an abnormally high number of white blood cells, causing the blood to clump and intrude on organ function. The leukapheresis procedure removes abnormal white blood cells while returning the rest of the blood to the patient whereas Myasthenia gravis is a condition in which unusual antibodies (proteins) in the blood interfere with nerve-muscle communication. Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that causes platelet clusters to establish all through the skin caused to a lack of a necessary blood enzyme.
The United Kingdom has one of the safest blood suppliers in the entire globe, and decisions about safety efforts are based on risk evidence, ethical considerations, and operational sustainability, as well as cost. When the evidence and/or the danger are unknown, SaBTO recommends precautionary advice. The SaBTO (Advisory Committee on the Safety of Blood, Tissues, and Organs) is an independent committee sponsored by the Ministry of Health and Social Care; members are chosen through an interview process following a public announcement. Representatives advise the four UK health ministers on the safety of blood, cells, tissues, and organs. Policies are available on the company's website and are updated regularly.
Advisory Committee on the Safety of Blood, Tissues and Organs reviews its recommendations on a regular basis, as well as when new information comes to light. The United Kingdom also has one of the world's premier haemovigilance organizations, which is in charge of collecting reports of transfusion-related adverse events so that the effect of policy decisions may be tracked.
The Germany market dominated the Europe Apheresis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $260.1 million by 2028. The UK market is poised to grow at a CAGR of 6.7% during (2022 - 2028). Additionally, The France market would display a CAGR of 8.4% during (2022 - 2028).
Based on Procedure, the market is segmented into Donor/Automated and Therapeutic. Based on Product, the market is segmented into Disposable & Reagents, Devices, and Software. Based on Method, the market is segmented into Centrifugation, Membrane Separation, and Selective Adsorption. Based on End User, the market is segmented into Blood Centers, Hospitals, and Others. Based on Component, the market is segmented into Plasma (Plasmapheresis), Platelets (Plateletpheresis), Leukocytes (Leukapheresis or leukopheresis), Lymphocytes (Lymphopheresis or lymphapheresis), and RBC's (Erythropheresis). Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Apheresis Market will Hit $4 Billion by 2028, at a CAGR of 8.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Asahi Kasei Medical Co., Ltd., Kaneka Corporation, Cerus Corporation, B. Braun Melsungen AG, Nikkiso Co., Ltd., Charles River Laboratories International, Inc., and SB Kawasumi Laboratories, Inc.
By Procedure
By Product
By Method
By End User
By Component
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
